Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abbisko Cayman Limited ( (HK:2256) ) has issued an update.
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has completed the first patient dosing in a Phase II clinical study of ABSK043, an oral small-molecule PD-L1 inhibitor, in combination with Glecirasib for treating non-small cell lung cancer (NSCLC) with KRAS G12C mutation. This milestone marks a significant advancement in the development of this treatment regimen, which aims to address a prevalent oncogenic driver in human cancer. The study, approved by China’s National Medical Products Administration, seeks to evaluate the safety and efficacy of this novel combination therapy, potentially impacting the company’s market positioning and offering new hope for patients with advanced NSCLC.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the pharmaceutical industry focusing on developing innovative cancer treatments. The company specializes in small-molecule inhibitors, with a particular emphasis on targeting oncogenic drivers such as PD-L1 and KRAS mutations.
Average Trading Volume: 5,505,344
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.9B
See more data about 2256 stock on TipRanks’ Stock Analysis page.